49
Assessment for
Response
c
Dabrafenib plus trametinib is FDA-approved for solid tumors with BRAF V600E mutation who
have progressed on prior treatment. Dabrafenib plus trametinib was not superior to Dabrafenib
alone in progressive DTC, thus Dabrafenib monotherapy may be considered.
d
Enrollment in a treatment clinical trial when available is encouraged. Other 3rd line options may
include lenvatinib, cabozantinib, or sorafenib if not already received.
Treatment
Decision
Assess
response and
continue if
treatment
tolerated and
no progression
3rd-line
therapy, only
in patients
with good
performance
status
d
Lenvatinib or
other MKI
Cabozantinib
or other MKI
Targeted therapy or
clinical trial,
if available
b
Dabrafenib +
trametinib
c
Disease
progression
